{
  "id": "fda_guidance_chunk_0768",
  "title": "Introduction - Part 768",
  "text": "No-treatment control (see 2.2), with design modifications,1 if appropriate · Any combination of above controls (see 1.3.6) Is the proven effective treatment life saving or known to prevent irreversible morbidity? ----- YES ----® Options · Active control; superiority, or non-inferiority if there is historical evidence of sensitivity to drug effect (see 1.5) · Placebo control with appropriate design modifications1 (e.g., add-on study) · Dose-response control (limited cases) NO ¯ Is there historical evidence of sensitivity to drug effects for an appropriately designed and conducted trial (see section 1.5) ---- NO ----® Options · Placebo control (see 2.1), with design modifications1, if appropriate · Dose-response control (see 2.3) · Active control showing superiority to control · No treatment control (see 2.2), with design modifications, if appropriate · Active and placebo controls (3-arm study; see 2.1.5.1.1) ¯ YES -----------------------------® Options · Placebo control (see 2.1), with design modifications, if appropriate · Dose-response control · Active control showing superiority to control · Active and placebo controls (3-arm study; see 2.1.5.1.1) · Active control non-inferiority (see 1.5) 1 Add-on, replacement, early escape, brief placebo period, and randomized withdrawal (see section 2.1.5.2). Guidance for Industry E9 Statistical Principles for Clinical Trials U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) September 1998 ICH Guidance for Industry E9 Statistical Principles for Clinical Trials Additional copies are available from: Office of Training and Communications Division of Drug Information (HFD-240) Center for Drug Evaluation and Research (CDER), 5600 Fishers Lane, Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm or Office of Communication, Training, and Manufacturers Assistance (HFM-40) Center for Biologics Evaluation and Research (CBER) 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/cber/guidelines.htm; (Fax) 888-CBERFAX or 301-827-3844 (Voice Information) 800-835-4709 or 301-827-1800 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) September 1998 ICH i TABLE OF CONTENTS I. INTRODUCTION.......................................................................................................................................................1 A. BACKGROUND AND PURPOSE (1.1) ...........................................................................................................................1 B. SCOPE AND DIRECTION (1.2).....................................................................................................................................2 II. CONSIDERATIONS FOR OVERALL CLINICAL DEVELOPMENT.................................................................4 A. TRIAL CONTEXT (2.1)................................................................................................................................................4 B. SCOPE OF TRIALS (2.2) .............................................................................................................................................6 C. DESIGN TECHNIQUES TO AVOID BIAS (2.3).............................................................................................................10 III. TRIAL DESIGN CONSIDERATIONS...................................................................................................................14 A. DESIGN CONFIGURATION (3.1)................................................................................................................................14 B. MULTICENTER TRIALS (3.2) ....................................................................................................................................16 C. TYPE OF COMPARISON (3.3)....................................................................................................................................18 D. GROUP",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 1030848,
  "end_pos": 1032384,
  "tokens": 512,
  "tags": [
    "efficacy",
    "design",
    "statistical",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "guidance",
  "created_at": "2025-10-23T02:25:44.737Z"
}